Get the app
public
ios_share
OncoPharm
chevron_right
Niraparib + Abiraterone, Elranatamab, & Melphalan Updates
Aug 17, 2023
14:25
forum
Ask episode
play_arrow
Play
view_agenda
Chapters
auto_awesome
Transcript
info_circle
Episode notes
A combination product is now available of niraparib + abiraterone for use in mCRPC. Another BCMA-CD3 agent is approved for r/r multiple myeloma and melphalan hepatic arterial infusion for metastatic uveal melanoma is approved.
